Waldenstrom’s macroglobulinaemia - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Waldenstrom’s macroglobulinaemia – Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Waldenstrom’s macroglobulinaemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Waldenstrom’s macroglobulinaemia: Overview
Waldenstrom’s macroglobulinaemia is a rare type of cancer that begins in the white blood cells. In this the bone marrow produces too many white blood cells that crowd out the normal healthy blood cells. Waldenstrom macroglobulinaemia is considered a type of non-Hodgkin's lymphoma. It's is also sometimes called lymphoplasmacytic lymphoma. Waldenstrom macroglobulinaemia is slow growing and may not cause signs and symptoms for many years. When they occur the symptoms may include: easy bruising, fatigue, weight loss, fever, numbness in hands and feet’s, change in vision and shortness of breath. What causes Waldenstrom’s macroglobulinaemia is still not clear. The disease generally begins with one abnormal white blood cell that develops errors (mutations) in its genetic code. The treatment options may include: chemotherapy, Plasma exchange, Targeted Therapy, Biological therapy and Bone marrow transplant.
'Waldenstrom’s macroglobulinaemia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Waldenstrom’s macroglobulinaemia pipeline landscape is provided which includes the disease overview and Waldenstrom’s macroglobulinaemia treatment guidelines. The assessment part of the report embraces, in depth Waldenstrom’s macroglobulinaemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Waldenstrom’s macroglobulinaemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Waldenstrom’s macroglobulinaemia R&D. The therapies under development are focused on novel approaches to treat/improve Waldenstrom’s macroglobulinaemia.
Waldenstrom’s macroglobulinaemia Emerging Drugs Chapters
This segment of the Waldenstrom’s macroglobulinaemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Waldenstrom’s macroglobulinaemia Emerging Drugs
BGB-3111: BeiGene
Zanubrutinib (BGB-3111) — a small molecule inhibitor of Bruton’s tyrosine kinase, or BTK, that is currently being evaluated in a broad late-stage clinical trials program globally, including in China, as a potential monotherapy and in combination with other therapies to treat various B cell malignancies. BGB-3111 has been registered for Waldenstrom's macroglobulinaemia in Canada.
ICP-022: Beijing InnoCare Pharma
ICP-022 (Orelabrutinib) is a specific and selective BTK inhibitor for the treatment of tumors and autoimmune diseases and has been supported by a national special project for the development of innovative drugs. Orelabrutinib is currently being investigated globally in broad clinical programs including Phase I, Phase II and registration trials as a monotherapy and in combination therapies. The drug is being evaluated in phase II stage of development for the treatment of Waldenstrom’s macroglobulinaemia.
ABT199: Abbvie
ABT-199 ( vnetoclax), which is a Bcl-2 inhibitor. Bcl-2 is an apoptosis regulator expressed in high levels in leukemia cells, and it is responsible for the prolonged survival of these cells. Venetoclax will block and modulate the activity of Bcl-2. The clinical trials for ABT199 are being evaluated in phase II stage of development for the treatment of Waldenstrom’s macroglobulinaemia in collaboration with Dana-Farber Cancer Institute.
Further product details are provided in the report……..
Waldenstrom’s macroglobulinaemia: Therapeutic Assessment
This segment of the report provides insights about the different Waldenstrom’s macroglobulinaemia drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Waldenstrom’s macroglobulinaemia
There are approx. 20+ key companies which are developing the therapies for Waldenstrom’s macroglobulinaemia. The companies which have their Waldenstrom’s macroglobulinaemia drug candidates in the most advanced stage, i.e. preregistration include, BeiGene.
Phases
DelveInsight’s report covers around 20+ products under different phases of clinical development like
Waldenstrom’s macroglobulinaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Waldenstrom’s macroglobulinaemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Waldenstrom’s macroglobulinaemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Waldenstrom’s macroglobulinaemia drugs.
Waldenstrom’s macroglobulinaemia Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Waldenstrom’s macroglobulinaemia – Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Waldenstrom’s macroglobulinaemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Waldenstrom’s macroglobulinaemia: Overview
Waldenstrom’s macroglobulinaemia is a rare type of cancer that begins in the white blood cells. In this the bone marrow produces too many white blood cells that crowd out the normal healthy blood cells. Waldenstrom macroglobulinaemia is considered a type of non-Hodgkin's lymphoma. It's is also sometimes called lymphoplasmacytic lymphoma. Waldenstrom macroglobulinaemia is slow growing and may not cause signs and symptoms for many years. When they occur the symptoms may include: easy bruising, fatigue, weight loss, fever, numbness in hands and feet’s, change in vision and shortness of breath. What causes Waldenstrom’s macroglobulinaemia is still not clear. The disease generally begins with one abnormal white blood cell that develops errors (mutations) in its genetic code. The treatment options may include: chemotherapy, Plasma exchange, Targeted Therapy, Biological therapy and Bone marrow transplant.
'Waldenstrom’s macroglobulinaemia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Waldenstrom’s macroglobulinaemia pipeline landscape is provided which includes the disease overview and Waldenstrom’s macroglobulinaemia treatment guidelines. The assessment part of the report embraces, in depth Waldenstrom’s macroglobulinaemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Waldenstrom’s macroglobulinaemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Waldenstrom’s macroglobulinaemia R&D. The therapies under development are focused on novel approaches to treat/improve Waldenstrom’s macroglobulinaemia.
Waldenstrom’s macroglobulinaemia Emerging Drugs Chapters
This segment of the Waldenstrom’s macroglobulinaemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Waldenstrom’s macroglobulinaemia Emerging Drugs
BGB-3111: BeiGene
Zanubrutinib (BGB-3111) — a small molecule inhibitor of Bruton’s tyrosine kinase, or BTK, that is currently being evaluated in a broad late-stage clinical trials program globally, including in China, as a potential monotherapy and in combination with other therapies to treat various B cell malignancies. BGB-3111 has been registered for Waldenstrom's macroglobulinaemia in Canada.
ICP-022: Beijing InnoCare Pharma
ICP-022 (Orelabrutinib) is a specific and selective BTK inhibitor for the treatment of tumors and autoimmune diseases and has been supported by a national special project for the development of innovative drugs. Orelabrutinib is currently being investigated globally in broad clinical programs including Phase I, Phase II and registration trials as a monotherapy and in combination therapies. The drug is being evaluated in phase II stage of development for the treatment of Waldenstrom’s macroglobulinaemia.
ABT199: Abbvie
ABT-199 ( vnetoclax), which is a Bcl-2 inhibitor. Bcl-2 is an apoptosis regulator expressed in high levels in leukemia cells, and it is responsible for the prolonged survival of these cells. Venetoclax will block and modulate the activity of Bcl-2. The clinical trials for ABT199 are being evaluated in phase II stage of development for the treatment of Waldenstrom’s macroglobulinaemia in collaboration with Dana-Farber Cancer Institute.
Further product details are provided in the report……..
Waldenstrom’s macroglobulinaemia: Therapeutic Assessment
This segment of the report provides insights about the different Waldenstrom’s macroglobulinaemia drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Waldenstrom’s macroglobulinaemia
There are approx. 20+ key companies which are developing the therapies for Waldenstrom’s macroglobulinaemia. The companies which have their Waldenstrom’s macroglobulinaemia drug candidates in the most advanced stage, i.e. preregistration include, BeiGene.
Phases
DelveInsight’s report covers around 20+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Waldenstrom’s macroglobulinaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Subcutaneous
- Intravenous
- Intramuscular
Products have been categorized under various Molecule types such as
- Bispecific Antibody
- Peptides
- Small molecule
- Gene therapy
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Waldenstrom’s macroglobulinaemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Waldenstrom’s macroglobulinaemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Waldenstrom’s macroglobulinaemia drugs.
Waldenstrom’s macroglobulinaemia Report Insights
- Waldenstrom’s macroglobulinaemia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Waldenstrom’s macroglobulinaemia drugs?
- How many Waldenstrom’s macroglobulinaemia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Waldenstrom’s macroglobulinaemia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Waldenstrom’s macroglobulinaemia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Waldenstrom’s macroglobulinaemia and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Waldenstrom’s macroglobulinaemia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Waldenstrom’s macroglobulinaemia – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Waldenstrom’s macroglobulinaemia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Waldenstrom’s macroglobulinaemia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
Comparative Analysis
BGB-3111: BeiGene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
ICP-022: Beijing InnoCare Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
LP168: Newave Pharmaceutical Inc
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical Stage Products
Comparative Analysis
Drug Name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Waldenstrom’s macroglobulinaemia Key Companies
Waldenstrom’s macroglobulinaemia Key Products
Waldenstrom’s macroglobulinaemia- Unmet Needs
Waldenstrom’s macroglobulinaemia- Market Drivers and Barriers
Waldenstrom’s macroglobulinaemia- Future Perspectives and Conclusion
Waldenstrom’s macroglobulinaemia Analyst Views
Waldenstrom’s macroglobulinaemia Key Companies
Appendix
Executive Summary
Waldenstrom’s macroglobulinaemia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Waldenstrom’s macroglobulinaemia – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Waldenstrom’s macroglobulinaemia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Waldenstrom’s macroglobulinaemia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
Comparative Analysis
BGB-3111: BeiGene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
ICP-022: Beijing InnoCare Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
LP168: Newave Pharmaceutical Inc
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical Stage Products
Comparative Analysis
Drug Name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Waldenstrom’s macroglobulinaemia Key Companies
Waldenstrom’s macroglobulinaemia Key Products
Waldenstrom’s macroglobulinaemia- Unmet Needs
Waldenstrom’s macroglobulinaemia- Market Drivers and Barriers
Waldenstrom’s macroglobulinaemia- Future Perspectives and Conclusion
Waldenstrom’s macroglobulinaemia Analyst Views
Waldenstrom’s macroglobulinaemia Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Waldenstrom’s macroglobulinaemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Waldenstrom’s macroglobulinaemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Waldenstrom’s macroglobulinaemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Waldenstrom’s macroglobulinaemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
